{
    "nctId": "NCT00461344",
    "briefTitle": "Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer",
    "officialTitle": "A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed \u2265 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere\u00ae- Based Chemotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Ductal Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Primary 1. to determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically verified breast cancer\n* Large (\u2265 3 cm) breast cancer\n* IIb-IIIa stage\n* ECOG (Eastern Cooperative Oncology Group) status: 0-1-2\n* Adequate bone marrow reserve: (Haemoglobin \u2265 12g/l, Absolute Neutrophil Count (ANC) \u2265 2.0x 10\\^9, Platelets \u2265100 000)\n* Laboratory results:\n* Bilirubin \u2264 Upper Limit Normal (ULN)\n* Serum Glutamate Pyruvate Transaminase (SGPT) \u2264 2.5 ULN, Serum Glutamate Oxaloacetate Transaminase (SGOT) \u2264 2.5 ULN,\n* Alk.phosph. \u2264 5.0 ULN,\n* Creatinin \u2264 ULN, if borderline calculated at \u2264 60ml/min\n* Normal cardiac function (the result of Left Ventricular Ejection Function (LVEF) must be above the lower limit of normal for the institution)\n* Negative pregnancy test\n* Hormonal receptor status assessed\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* SGOT and/or SGPT \\> 1.5 upper limit normal, associated with Alk.phosph \\> 2.5 ULN\n* Serious medical condition including but not limited to:\n* Uncontrolled hypertension\n* Active ulcus pepticum\n* Non-stable diabetes mellitus\n* Other contraindication of steroid treatment\n* Myocardial infarction within the last 6 months prior study entry\n* Significant neurologic/psychiatric disorders\n* Active infection\n* Peripheral neuropathy grade \u2265 2\n* Unstable angina\n* Severe arrhythmia\n* Participation in other clinical trial\n* Prior surgery, chemotherapy, hormonotherapy for breast cancer\n* Past or current history of neoplasm other than breast cancer, except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 7 years\n* History of hypersensitivity to the investigational products or to drugs with similar chemical structures\n* Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol\n* Treatment with any investigational product in the last 1 month before study entry.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}